Overview
As H. pylori eradication, the investigators prepared a randomized controlled clinical trial whether tegoprazan-containing 10-day sequential treatment was effective compared to conventional PPI-containing 10-day sequential eradication therapy
Description
Eradication treatment containing potassium-competitive acid blocker has shown acceptable eradication efficacy. In regions such as Korea, where the prevalence of antimicrobial resistance is high, alternative combinations of antibiotics such as sequential or concomitant therapy are needed. This study compared the outcome of sequential therapy containing tegoprazan, a new potassium-competitive acid blocker, with the conventional esomeprazole-containing sequential therapy.
Eligibility
Inclusion Criteria:
Patients who had H. pylori infection proved by positive test result of urea breath test
(UBT), rapid urase test or pathologic examination (warthin-giemsa staining)
Exclusion Criteria:
- congestive heart failure, NYHA III or IV
- end-stage renal disease
- alcoholics
- drug abusers
- pregnant or nursing women